Fluoroquinolone resistance in multidrug-resistant <i>Mycobacterium tuberculosis</i> independent of fluoroquinolone use

Chen, Yang; Song, Qifan; Yang, Tianchi; GuoHua, Ping; Yu, Mengxue

doi:10.1183/13993003.01633-2017

Cited by 10 publications

(5 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…High frequency MDR and XDR-TB in the present study may be attributed to inclusion of very sick patients from our tertiary care TB hospital which were more likely to be drug resistant. Previous studies described high frequency of fluoroquinolone among MDR-TB/rifampicin-resistant TB (RR-TB) patients [30] , [31] . The present study observed high frequency of MDR-TB and hence, this may be the reason of high frequency of ofloxacin (a fluoroquinolone) resistance encountered in this study.…”

Section: Discussionmentioning

confidence: 99%

Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains in geriatrics: An analysis and its implications in tuberculosis control

Verma

Yadav

Kumar

et al. 2022

Journal of Clinical Tuberculosis and Other Mycobacterial Diseas

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains in geriatrics: An analysis and its implications in tuberculosis control

Verma

Yadav

Kumar

et al. 2022

Journal of Clinical Tuberculosis and Other Mycobacterial Diseas

View full text Add to dashboard Cite

“…For the two newer FQs, our data revealed that 50.0% of MDR-TB strains were resistant to LFX, and 38.6% resistant to MFX in southwest of China. A study from mid-East of China showed that 37% of uoroquinolone resistance events were in MDR M. tuberculosis isolates [10]. And a total of 76% LFX resistance and 73% MFX resistance MTB isolates were identi ed in a study from southern China [11].…”

Section: Discussionmentioning

confidence: 99%

Molecular Characterization of Levofloxacin, Moxifloxacin, Bedaquiline, Linezolid, Clofazimine, and Delamanid against Multidrug-resistant Tuberculosis in Southwest of China

He¹,

Jiao²,

Xing³

et al. 2021

Preprint

View full text Add to dashboard Cite

Objectives: To explore the drug susceptibility of levofloxacin (LFX), moxifloxacin (MFX), bedaquiline (BDQ), linezolid (LZD), clofazimine (CFZ) and delamanid (DLM) against multidrug resistant tuberculosis (MDR-TB) isolates from drug resistance survey of southwest China, and to illustrate the genetic characteristics of MDR-TB isolates with acquired drug resistance. Methods: A total of 339 strains were collected from smear-positive TB patients in the drug resistance survey of southwest China between January 2014 and December 2016. The MICs were determined for MDR-TB identified by conventional drug susceptibility testing. Genes related to drug resistance were amplified with their corresponding pairs of primers. Results: MDR was observed in 88 (26.0%; 88/339) isolates. LFX had the highest resistance rate (50.0%; 44/88), followed by MFX (38.6%; 34/88). The resistance rate to LZD, CFZ, and DLM was 4.5% (4/88), 3.4% (3/88), and 4.5% (4/88), respectively, and the lowest resistance rate was observed in BDQ (2.3%; 2/88). Of the 45 isolates resistant to LFX and MFX, the most prevalent resistance mutation was found in gyrA with the substitution of codon 94 (34/45, 75.6%). All two CFZ - BDQ cross resistant strains had a mutation in the Rv0678 gene. Two of four LZD resistant isolates carried mutations in rplC gene. Of the four isolates resistant to DLM, one isolate with the mutations in codon 318 of fbiC gene and two isolates in codon 81 of ddn gene. Conclusion: This study provided evidence for further application of new anti-TB drugs in the treatment of MDR-TB in China.

show abstract

“…12,13 Many other studies from different regions have also demonstrated weak relationship between prior FQ use and FQ resistance. [14][15][16] The correlation between resistance to a drug (other than rifampicin and isoniazid) and prior intake of the same drug was not found to be statistically significant for any drug. According to a study by Hamusse et al, individuals with previous history of TB treatment were eight times more likely to develop resistance to any first-line anti-TB drugs compared to those with no history of previous TB treatment.…”

Section: Discussionmentioning

confidence: 99%

Drug resistance profile among multi-drug resistant tuberculosis patients at diagnosis and correlation with history of anti-tubercular treatment in a tertiary care center

et al. 2019

View full text Add to dashboard Cite

Background: Drug Resistant Tuberculosis (DR-TB) is a major threat to the realization of the goal of a TB free world in the near future. It is important to study the reasons for the increasing number of such cases so that effective action can be taken to control this growing epidemic.Methods: Sputum from 36 patients diagnosed with acquired pulmonary Multidrug Resistant Tuberculosis (MDR-TB) were subjected to first- and second-line Drug Sensitivity Testing (DST) after liquid culture in mycobacterium growth Indicator Tube (MGIT). Primary MDR-TB cases were excluded. The relation of the drug sensitivity profile with the history of prior treatment taken was statistically analysed.Results: Majority of the patients had received appropriate treatment, and most had adhered to prescribed treatment. Among the 36 patients, 24(66.7%) were found to be Pre-Extensively Drug Resistant (Pre-XDR-TB) and 4(11.1%) were extensively drug resistant XDR-TB cases. Inappropriate prescription of fluoroquinolone (FQ) was found to be most common. Prior intake of any drug was not found to significantly affect subsequent resistance to that drug.Conclusions: Fluoroquinolone resistance is quite common in patients with DR-TB (66.7%). This study did not find the prior use of FQ or any other drug to significantly affect subsequent resistance to the drug. Primary drug resistance is thus a major concern. 11.1% patients were found to be XDR-TB cases. Hence DST for first- and second-line drugs should be done at the time of diagnosis to avoid failure of treatment with a predesigned regimen.

show abstract

Fluoroquinolone resistance in multidrug-resistant Mycobacterium tuberculosis independent of fluoroquinolone use

Cited by 10 publications

References 16 publications

Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains in geriatrics: An analysis and its implications in tuberculosis control

Multidrug-resistant and extensively drug-resistant Mycobacterium tuberculosis strains in geriatrics: An analysis and its implications in tuberculosis control

Molecular Characterization of Levofloxacin, Moxifloxacin, Bedaquiline, Linezolid, Clofazimine, and Delamanid against Multidrug-resistant Tuberculosis in Southwest of China

Drug resistance profile among multi-drug resistant tuberculosis patients at diagnosis and correlation with history of anti-tubercular treatment in a tertiary care center

Contact Info

Product

Resources

About